Westfield Bank (the “Bank”), a wholly owned subsidiary of Westfield
Financial, Inc. (NasdaqGS:WFD), announced that Linda Swartz, Vice
President of Security and Fraud Investigations, is scheduled to appear
on the CBS News program “60 Minutes” on Sunday, November 30, 2014.
Binkow & Goldberg LLP reminds investors of Arrowhead
Research Corporation (“Arrowhead” or the “Company”) (NASDAQ:ARWR)
that purchasers of Arrowhead common stock between August 12, 2014 and
October 8, 2014, inclusive (the “Class Period”), have until December 9,
2014, to file a motion to be appointed as lead plaintiff in the
shareholder lawsuit filed in the United States District Court for the
Central District of California.
By Carla Mozee, MarketWatch Nomura turns bullish on the luxury-goods sector
LONDON (MarketWatch)--European stocks ended with a whimper Wednesday, giving up a stronger lead following three straight sessions of advances.
By Philip van Doorn, MarketWatch Phil van Doorn presents this year's biggest losers in six market sectors
On the day before Thanksgiving, it seems appropriate to highlight some of the year's biggest turkeys in the stock market.
Company Ticker Industry Sales per share - past three quarters Sales per share - year earlier Change in sales per share Total return - YTD
Avon Products Inc. Household/ Personal Care $14.99 $16.87 -11% -42%
Coach Inc. Apparel/ Footwear Retail $11.81 $12.50 -6% -32%
Mattel Inc. Recreational Products $11.84 $12.56 -6% -32%
Discovery Communications Inc. Class A Media Conglomerates $10.97
WEST PALM BEACH, FL --
Innovative Solutions & Support, Inc. (NASDAQ:ISSC) announced today the
Company will release results for the fourth quarter and fiscal year end
2014 results (period ended September 30, 2014) on Wednesday, December 3,
2014 after the market closes.
Squibb Company (NYSE:BMY) today announced that the U.S. Food and
Drug Administration (FDA) has issued a Complete Response Letter (CRL)
regarding the New Drug Application (NDA) for daclatasvir, an NS5A
complex inhibitor, in combination with other agents for the treatment of
hepatitis C (HCV).
The initial daclatasvir NDA submitted to the FDA focused on its use in
combination with asunaprevir, an NS3/4A protease inhibitor.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.